454 related articles for article (PubMed ID: 29567429)
1. Design, synthesis and biological evaluation of novel 1,3,4-trisubstituted pyrazole derivatives as potential chemotherapeutic agents for hepatocellular carcinoma.
Harras MF; Sabour R
Bioorg Chem; 2018 Aug; 78():149-157. PubMed ID: 29567429
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and biological evaluation of novel pyrazolic chalcone derivatives as novel hepatocellular carcinoma therapeutics.
Hawash MM; Kahraman DC; Eren F; Cetin Atalay R; Baytas SN
Eur J Med Chem; 2017 Mar; 129():12-26. PubMed ID: 28219046
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, biological evaluation, and modeling studies of novel conformationally-restricted analogues of sorafenib as selective kinase-inhibitory antiproliferative agents against hepatocellular carcinoma cells.
Sbenati RM; Zaraei SO; El-Gamal MI; Anbar HS; Tarazi H; Zoghbor MM; Mohamood NA; Khakpour MM; Zaher DM; Omar HA; Alach NN; Shehata MK; El-Gamal R
Eur J Med Chem; 2021 Jan; 210():113081. PubMed ID: 33310290
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and biological evaluation of N-((1-benzyl-1H-1,2,3-triazol-4-yl)methyl)-1,3-diphenyl-1H-pyrazole-4-carboxamides as CDK1/Cdc2 inhibitors.
Ganga Reddy V; Srinivasa Reddy T; Lakshma Nayak V; Prasad B; Reddy AP; Ravikumar A; Taj S; Kamal A
Eur J Med Chem; 2016 Oct; 122():164-177. PubMed ID: 27344493
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and biological evaluation of pyrazole derivatives as potential multi-kinase inhibitors in hepatocellular carcinoma.
Strocchi E; Fornari F; Minguzzi M; Gramantieri L; Milazzo M; Rebuttini V; Breviglieri S; Camaggi CM; Locatelli E; Bolondi L; Comes-Franchini M
Eur J Med Chem; 2012 Feb; 48():391-401. PubMed ID: 22227043
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and biological evaluation of certain CDK2 inhibitors based on pyrazole and pyrazolo[1,5-a] pyrimidine scaffold with apoptotic activity.
Ali GME; Ibrahim DA; Elmetwali AM; Ismail NSM
Bioorg Chem; 2019 May; 86():1-14. PubMed ID: 30682722
[TBL] [Abstract][Full Text] [Related]
7. Discovery of 5-aryl-3-thiophen-2-yl-1H-pyrazoles as a new class of Hsp90 inhibitors in hepatocellular carcinoma.
Mohamady S; Ismail MI; Mogheith SM; Attia YM; Taylor SD
Bioorg Chem; 2020 Jan; 94():103433. PubMed ID: 31785857
[TBL] [Abstract][Full Text] [Related]
8. Novel pyrazolo[3,4-d]pyrimidines: design, synthesis, anticancer activity, dual EGFR/ErbB2 receptor tyrosine kinases inhibitory activity, effects on cell cycle profile and caspase-3-mediated apoptosis.
Maher M; Kassab AE; Zaher AF; Mahmoud Z
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):532-546. PubMed ID: 30688116
[TBL] [Abstract][Full Text] [Related]
9. Design, Synthesis, and Biological Evaluation of Novel Thiazolyl Substituted Bis-pyrazole Oxime Derivatives with Potent Antitumor Activities by Selectively Inducing Apoptosis and ROS in Cancer Cells.
Xiong B; Chen S; Zhu P; Huang M; Gao W; Zhu R; Qian J; Peng Y; Zhang Y; Dai H; Ling Y
Med Chem; 2019; 15(7):743-754. PubMed ID: 30147012
[TBL] [Abstract][Full Text] [Related]
10. Anti‑cancer effects of a novel Pan‑RAF inhibitor in a hepatocellular carcinoma cell line.
Wang W; Xu B; Li Q; Jiang D; Yan S
Mol Med Rep; 2018 Apr; 17(4):6185-6193. PubMed ID: 29484394
[TBL] [Abstract][Full Text] [Related]
11. The anti-hepatocellular carcinoma cell activity by a novel mTOR kinase inhibitor CZ415.
Zhang W; Chen B; Zhang Y; Li K; Hao K; Jiang L; Wang Y; Mou X; Xu X; Wang Z
Biochem Biophys Res Commun; 2017 Jun; 487(3):494-499. PubMed ID: 28366631
[TBL] [Abstract][Full Text] [Related]
12. Synthesis of stable benzimidazole derivatives bearing pyrazole as anticancer and EGFR receptor inhibitors.
Akhtar MJ; Khan AA; Ali Z; Dewangan RP; Rafi M; Hassan MQ; Akhtar MS; Siddiqui AA; Partap S; Pasha S; Yar MS
Bioorg Chem; 2018 Aug; 78():158-169. PubMed ID: 29571113
[TBL] [Abstract][Full Text] [Related]
13. Synthesis, in vitro Antiproliferative and Antiinflammatory Activities, and Kinase Inhibitory effects of New 1,3,4-triarylpyrazole Derivatives.
El-Gamal MI; Abdel-Maksoud MS; Gamal El-Din MM; Shin JS; Lee KT; Yoo KH; Oh CH
Anticancer Agents Med Chem; 2017; 17(1):75-84. PubMed ID: 27334850
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, molecular modelling, and biological evaluation of novel substituted pyrimidine derivatives as potential anticancer agents for hepatocellular carcinoma.
Ahmed NM; Youns M; Soltan MK; Said AM
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1110-1120. PubMed ID: 31117890
[TBL] [Abstract][Full Text] [Related]
15. Synthesis of novel diflunisal hydrazide-hydrazones as anti-hepatitis C virus agents and hepatocellular carcinoma inhibitors.
Şenkardeş S; Kaushik-Basu N; Durmaz İ; Manvar D; Basu A; Atalay R; Küçükgüzel ŞG
Eur J Med Chem; 2016 Jan; 108():301-308. PubMed ID: 26695731
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and screening of ortho-amino thiophene carboxamide derivatives on hepatocellular carcinomaas VEGFR-2Inhibitors.
AbdElhameid MK; Labib MB; Negmeldin AT; Al-Shorbagy M; Mohammed MR
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):1472-1493. PubMed ID: 30191744
[TBL] [Abstract][Full Text] [Related]
17. Synthesis, in vitro anticancer activity and in silico studies of certain pyrazole-based derivatives as potential inhibitors of cyclin dependent kinases (CDKs).
Mohammed EZ; Mahmoud WR; George RF; Hassan GS; Omar FA; Georgey HH
Bioorg Chem; 2021 Nov; 116():105347. PubMed ID: 34555628
[TBL] [Abstract][Full Text] [Related]
18. Synthesis, EGFR Inhibition and Anti-cancer Activity of New 3,6-dimethyl-1-phenyl-4-(substituted-methoxy)pyrazolo[3,4-d] pyrimidine Derivatives.
Bakr RB; Mehany ABM; Abdellatif KRA
Anticancer Agents Med Chem; 2017; 17(10):1389-1400. PubMed ID: 28270084
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and anticancer evaluation of 1H-pyrazolo[3,4-d]pyrimidine derivatives as potent EGFR
Gaber AA; Bayoumi AH; El-Morsy AM; Sherbiny FF; Mehany ABM; Eissa IH
Bioorg Chem; 2018 Oct; 80():375-395. PubMed ID: 29986185
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, and biological evaluation of indazole derivatives as selective and potent FGFR4 inhibitors for the treatment of FGF19-driven hepatocellular cancer.
Chen X; Liu Y; Zhang L; Chen D; Dong Z; Zhao C; Liu Z; Xia Q; Wu J; Chen Y; Zheng X; Cai Y
Eur J Med Chem; 2021 Mar; 214():113219. PubMed ID: 33618175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
